MedPath

Effect of leech therapy in increased d-dimer laboratory values.

Phase 2
Conditions
Health Condition 1: D689- Coagulation defect, unspecifiedHealth Condition 2: D65- Disseminated intravascular coagulation [defibrination syndrome]Health Condition 3: I829- Embolism and thrombosis of unspecified veinHealth Condition 4: I998- Other disorder of circulatory systemHealth Condition 5: D686- Other thrombophiliaHealth Condition 6: I838- Varicose veins of lower extremities with other complications
Registration Number
CTRI/2022/12/048609
Lead Sponsor
Dr Nikita Saxena
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients those have increased D-dimer values in Deep vein thrombosis (DVT), Disseminated intravascular coagulation, Hepatomegaly and Post convalescence SARS Covid-19 patients(after 3 months)will be selected for study.

2.Participants of any gender in between 16 to 70 ages.

3.Participants who are willing for the study.

Exclusion Criteria

1.Absolute Hemophiliac and other bleeding disorders.

2.Anticoagulant medicines like Warfarin, Heparin, etc.

3.Severe Anemia.

4.Erosive Gastritis and potential gastrointestinal bleeding.

5.During Chemotherapy.

6.Individuals with HIV infection.

7.Severe Allergic Diathesis (allergy foreign proteins).

8.Hypotension

9.Active Tuberculosis.

10.Pregnancy

11.Mental disorders during acute episodes.

12.Severe ill and bed patient.

13.Acute DVT

14.Pulmonary Embolism

15.Malignancy

16.Participants who are known cases of renal failure, neurological, Diagnosed with CA, and also with psychological disturbances.

17.Uncontrolled systemic conditions like Diabetes mellitus.

18.Cirrhosis of the Liver

19.Coagulopathies.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath